These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37383884)

  • 1. The impact of external reference pricing on pharmaceutical costs and market dynamics.
    Voehler D; Koethe BC; Synnott PG; Ollendorf DA
    Health Policy Open; 2023 Dec; 4():100093. PubMed ID: 37383884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External Reference Pricing for Pharmaceuticals-A Survey and Literature Review to Describe Best Practices for Countries With Expanding Healthcare Coverage.
    Holtorf AP; Gialama F; Wijaya KE; Kaló Z
    Value Health Reg Issues; 2019 Sep; 19():122-131. PubMed ID: 31416014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overview of external reference pricing systems in Europe.
    Rémuzat C; Urbinati D; Mzoughi O; El Hammi E; Belgaied W; Toumi M
    J Mark Access Health Policy; 2015; 3():. PubMed ID: 27123181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How does external reference pricing work in developing countries: evidence from Iran.
    Babaie F; Motevalli MH; Mehralian G; Peiravian F; Yousefi N
    Front Pharmacol; 2023; 14():1034229. PubMed ID: 37408767
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of regulation on drug launch and pricing in interdependent markets.
    Danzon PM; Epstein AJ
    Adv Health Econ Health Serv Res; 2012; 23():35-71. PubMed ID: 23156660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International impact of external reference pricing: should national policy-makers care?
    Fontrier AM; Gill J; Kanavos P
    Eur J Health Econ; 2019 Nov; 20(8):1147-1164. PubMed ID: 31289948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does external reference pricing deliver what it promises? Evidence on its impact at national level.
    Kanavos P; Fontrier AM; Gill J; Efthymiadou O
    Eur J Health Econ; 2020 Feb; 21(1):129-151. PubMed ID: 31583483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pricing of in-patent pharmaceuticals in the Middle East and North Africa: Is external reference pricing implemented optimally?
    Kanavos P; Kamphuis BW; Fontrier AM; Colville Parkin G; Saleh S; Akhras KS
    Health Policy; 2020 Dec; 124(12):1297-1309. PubMed ID: 32962876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Reference Pricing for Prescription Drugs in the United States: Administrative Limitations and Collateral Effects.
    Rand LZ; Kesselheim AS
    Value Health; 2021 Apr; 24(4):473-476. PubMed ID: 33840424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of European pharmaceutical price regulation on generic price competition: a review.
    Puig-Junoy J
    Pharmacoeconomics; 2010; 28(8):649-63. PubMed ID: 20515079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using External Reference Pricing In Medicare Part D To Reduce Drug Price Differentials With Other Countries.
    Kang SY; DiStefano MJ; Socal MP; Anderson GF
    Health Aff (Millwood); 2019 May; 38(5):804-811. PubMed ID: 31059372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing the Consequences of External Reference Pricing for Global Access to Medicines and Innovation: Economic Analysis and Policy Implications.
    Incze A; Kaló Z; Espín J; Kiss É; Kessabi S; Garrison LP
    Front Pharmacol; 2022; 13():815029. PubMed ID: 35462921
    [No Abstract]   [Full Text] [Related]  

  • 14. Impact of cross-reference pricing on pharmaceutical prices: manufacturers' pricing strategies and price regulation.
    Stargardt T; Schreyögg J
    Appl Health Econ Health Policy; 2006; 5(4):235-47. PubMed ID: 17249840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe.
    Vokinger KN; Hwang TJ; Daniore P; Lee CC; Tibau A; Grischott T; Rosemann TJ; Kesselheim AS
    JAMA Oncol; 2021 Sep; 7(9):e212026. PubMed ID: 34196656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad.
    Mattingly TJ; Seo D; Ostrovsky AM; Vanness DJ; Conti RM
    Res Social Adm Pharm; 2021 Aug; 17(8):1489-1495. PubMed ID: 33221266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
    Aaserud M; Dahlgren AT; Kösters JP; Oxman AD; Ramsay C; Sturm H
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005979. PubMed ID: 16625648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal price regulations in international pharmaceutical markets with generic competition.
    Geng D; Saggi K
    J Health Econ; 2020 May; 71():102315. PubMed ID: 32273046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physician and Patient Adjustment to Reference Pricing for Drugs.
    Robinson JC; Whaley C; Brown TT; Dhruva SS
    JAMA Netw Open; 2020 Feb; 3(2):e1920544. PubMed ID: 32022881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indication-wide drug pricing: Insights from the pharma market.
    Siegmeier F; Büssgen M
    J Pharm Policy Pract; 2022 Aug; 15(1):53. PubMed ID: 36038951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.